TABRECTA is the first treatment that specifically treats people with mNSCLC who have METex14.
Learn more about TABRECTA
Understanding METex14
In Metastatic Non-Small Cell Lung Cancer
MET exon 14 skipping
Non-small cell lung cancer (NSCLC) is not just 1 disease, but many types of disease with specific genetic differences. Certain people may have noninherited gene mutations that can cause their cancer cells to grow and multiply.
METex14 is caused by mutations in the MET gene
-
Gene changes (mutations) have been linked to cancer growth in metastatic non-small cell lung cancer (mNSCLC)
- Certain noninherited gene mutations can cause MET exon 14 skipping (METex14), which is an abnormal change in a gene that makes a protein called mesenchymal-epithelial transition (MET)
-
METex14 has been linked to cancer growth in mNSCLC
-
METex14 can be detected by an FDA-approved comprehensive biomarker test
- For people with mNSCLC with METex14, there is an option to take the first FDA-approved targeted therapy, TABRECTA® (capmatinib) tablets
